{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:06:50Z","timestamp":1790474810497,"version":"4.1.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T00:00:00Z","timestamp":1493683200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s11904-017-0357-9","type":"journal-article","created":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T03:16:26Z","timestamp":1493694986000},"page":"101-109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Mechanisms of HIV-1 Control"],"prefix":"10.1007","volume":"14","author":[{"given":"Mary","family":"Soliman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geetha","family":"Srikrishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Balagopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,2]]},"reference":[{"issue":"4","key":"357_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/ni.3123","volume":"16","author":"A Iwasaki","year":"2015","unstructured":"Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol. 2015;16(4):343\u201353. doi:\n10.1038\/ni.3123\n\n.","journal-title":"Nat Immunol"},{"key":"357_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1146\/annurev-immunol-032414-112240","volume":"33","author":"SW Brubaker","year":"2015","unstructured":"Brubaker SW, Bonham KS, Zanoni I, Kagan JC. Innate immune pattern recognition: a cell biological perspective. Annu Rev Immunol. 2015;33:257\u201390. doi:\n10.1146\/annurev-immunol-032414-112240\n\n.","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"357_CR3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cytogfr.2014.08.006","volume":"25","author":"N Montfoort van","year":"2014","unstructured":"van Montfoort N, Olagnier D, Hiscott J. Unmasking immune sensing of retroviruses: interplay between innate sensors and host effectors. Cytokine Growth Factor Rev. 2014;25(6):657\u201368. doi:\n10.1016\/j.cytogfr.2014.08.006\n\n.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"5","key":"357_CR4","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.cytogfr.2014.07.002","volume":"25","author":"SE Collins","year":"2014","unstructured":"Collins SE, Mossman KL. Danger, diversity and priming in innate antiviral immunity. Cytokine Growth Factor Rev. 2014;25(5):525\u201331. doi:\n10.1016\/j.cytogfr.2014.07.002\n\n.","journal-title":"Cytokine Growth Factor Rev"},{"key":"357_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.coi.2014.12.003","volume":"32","author":"A Silvin","year":"2015","unstructured":"Silvin A, Manel N. Innate immune sensing of HIV infection. Curr Opin Immunol. 2015;32:54\u201360. doi:\n10.1016\/j.coi.2014.12.003\n\n.","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"357_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nri3787","volume":"15","author":"F McNab","year":"2015","unstructured":"McNab F, Mayer-Barber K, Sher A, Wack A, O\u2019Garra A. Type I interferons in infectious disease. Nat Rev Immunol. 2015;15(2):87\u2013103. doi:\n10.1038\/nri3787\n\n.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"357_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nri3344","volume":"13","author":"MS Diamond","year":"2013","unstructured":"Diamond MS, Farzan M. The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat Rev Immunol. 2013;13(1):46\u201357. doi:\n10.1038\/nri3344\n\n.","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"357_CR8","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.cell.2009.12.017","volume":"139","author":"AL Brass","year":"2009","unstructured":"Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM, et al. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell. 2009;139(7):1243\u201354. doi:\n10.1016\/j.cell.2009.12.017\n\n.","journal-title":"Cell"},{"issue":"5","key":"357_CR9","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1128\/JVI.01531-10","volume":"85","author":"J Lu","year":"2011","unstructured":"Lu J, Pan Q, Rong L, He W, Liu SL, Liang C. The IFITM proteins inhibit HIV-1 infection. J Virol. 2011;85(5):2126\u201337. doi:\n10.1128\/JVI.01531-10\n\n.","journal-title":"J Virol"},{"issue":"10","key":"357_CR10","doi-asserted-by":"publisher","first-page":"e1002337","DOI":"10.1371\/journal.ppat.1002337","volume":"7","author":"EM Feeley","year":"2011","unstructured":"Feeley EM, Sims JS, John SP, Chin CR, Pertel T, Chen LM, et al. IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog. 2011;7(10):e1002337. doi:\n10.1371\/journal.ppat.1002337\n\n.","journal-title":"PLoS Pathog"},{"issue":"9","key":"357_CR11","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1111\/tra.12416","volume":"17","author":"S Weston","year":"2016","unstructured":"Weston S, Czieso S, White IJ, Smith SE, Wash RS, Diaz-Soria C, et al. Alphavirus restriction by IFITM proteins. Traffic. 2016;17(9):997\u20131013. doi:\n10.1111\/tra.12416\n\n.","journal-title":"Traffic"},{"issue":"3","key":"357_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cell.2005.10.015","volume":"123","author":"LV Chernomordik","year":"2005","unstructured":"Chernomordik LV, Kozlov MM. Membrane hemifusion: crossing a chasm in two leaps. Cell. 2005;123(3):375\u201382. doi:\n10.1016\/j.cell.2005.10.015\n\n.","journal-title":"Cell"},{"issue":"1","key":"357_CR13","doi-asserted-by":"publisher","first-page":"e1003124","DOI":"10.1371\/journal.ppat.1003124","volume":"9","author":"K Li","year":"2013","unstructured":"Li K, Markosyan RM, Zheng YM, Golfetto O, Bungart B, Li M, et al. IFITM proteins restrict viral membrane hemifusion. PLoS Pathog. 2013;9(1):e1003124. doi:\n10.1371\/journal.ppat.1003124\n\n.","journal-title":"PLoS Pathog"},{"issue":"24","key":"357_CR14","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.2174\/156802611798808479","volume":"11","author":"H Garg","year":"2011","unstructured":"Garg H, Viard M, Jacobs A, Blumenthal R. Targeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapy. Curr Top Med Chem. 2011;11(24):2947\u201358.","journal-title":"Curr Top Med Chem"},{"issue":"6","key":"357_CR15","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.chom.2014.11.001","volume":"16","author":"AA Compton","year":"2014","unstructured":"\u2022\u2022 Compton AA, Bruel T, Porrot F, Mallet A, Sachse M, Euvrard M, et al. IFITM proteins incorporated into HIV-1 virions impair viral fusion and spread. Cell Host Microbe. 2014;16(6):736\u201347. doi:\n10.1016\/j.chom.2014.11.001\n\n. A paper showing a mechanism in which IFITM incorporates itself into virions to block fusion","journal-title":"Cell Host Microbe"},{"issue":"1","key":"357_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.celrep.2015.08.055","volume":"13","author":"J Yu","year":"2015","unstructured":"\u2022\u2022 Yu J, Li M, Wilkins J, Ding S, Swartz TH, Esposito AM, et al. IFITM proteins restrict HIV-1 infection by antagonizing the envelope glycoprotein. Cell Rep. 2015;13(1):145\u201356. doi:\n10.1016\/j.celrep.2015.08.055\n\n. A paper showing how IFITM acts by inhibiting production and incrporation of envelope proteins","journal-title":"Cell Rep"},{"key":"357_CR17","doi-asserted-by":"publisher","unstructured":"Foster TL, Wilson H, Iyer SS, Coss K, Doores K, Smith S et al. 2016. Resistance of transmitted founder HIV-1 to IFITM-mediated restriction. Cell host & microbe. doi: \n10.1016\/j.chom.2016.08.006","DOI":"10.1016\/j.chom.2016.08.006"},{"issue":"6977","key":"357_CR18","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/nature02343","volume":"427","author":"M Stremlau","year":"2004","unstructured":"Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature. 2004;427(6977):848\u201353. doi:\n10.1038\/nature02343\n\n.","journal-title":"Nature"},{"issue":"10","key":"357_CR19","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/nrmicro1248","volume":"3","author":"S Nisole","year":"2005","unstructured":"Nisole S, Stoye JP, Saib A. TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol. 2005;3(10):799\u2013808. doi:\n10.1038\/nrmicro1248\n\n.","journal-title":"Nat Rev Microbiol"},{"issue":"12","key":"357_CR20","doi-asserted-by":"publisher","first-page":"e1002388","DOI":"10.1371\/journal.pgen.1002388","volume":"7","author":"K Han","year":"2011","unstructured":"Han K, Lou DI, Sawyer SL. Identification of a genomic reservoir for new TRIM genes in primate genomes. PLoS Genet. 2011;7(12):e1002388. doi:\n10.1371\/journal.pgen.1002388\n\n.","journal-title":"PLoS Genet"},{"issue":"2","key":"357_CR21","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.virol.2006.05.035","volume":"353","author":"F Zhang","year":"2006","unstructured":"Zhang F, Hatziioannou T, Perez-Caballero D, Derse D, Bieniasz PD. Antiretroviral potential of human tripartite motif-5 and related proteins. Virology. 2006;353(2):396\u2013409. doi:\n10.1016\/j.virol.2006.05.035\n\n.","journal-title":"Virology"},{"issue":"21","key":"357_CR22","doi-asserted-by":"publisher","first-page":"11010","DOI":"10.1128\/JVI.00758-10","volume":"84","author":"E Battivelli","year":"2010","unstructured":"Battivelli E, Lecossier D, Matsuoka S, Migraine J, Clavel F, Hance AJ. Strain-specific differences in the impact of human TRIM5alpha, different TRIM5alpha alleles, and the inhibition of capsid-cyclophilin A interactions on the infectivity of HIV-1. J Virol. 2010;84(21):11010\u20139. doi:\n10.1128\/JVI.00758-10\n\n.","journal-title":"J Virol"},{"issue":"9","key":"357_CR23","doi-asserted-by":"publisher","first-page":"e1003667","DOI":"10.1371\/journal.ppat.1003667","volume":"9","author":"SJ Soll","year":"2013","unstructured":"Soll SJ, Wilson SJ, Kutluay SB, Hatziioannou T, Bieniasz PD. Assisted evolution enables HIV-1 to overcome a high TRIM5alpha-imposed genetic barrier to rhesus macaque tropism. PLoS Pathog. 2013;9(9):e1003667. doi:\n10.1371\/journal.ppat.1003667\n\n.","journal-title":"PLoS Pathog"},{"issue":"2","key":"357_CR24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.virol.2006.10.035","volume":"360","author":"X Li","year":"2007","unstructured":"Li X, Gold B, O\u2019HUigin C, Diaz-Griffero F, Song B, Si Z, et al. Unique features of TRIM5alpha among closely related human TRIM family members. Virology. 2007;360(2):419\u201333. doi:\n10.1016\/j.virol.2006.10.035\n\n.","journal-title":"Virology"},{"issue":"3","key":"357_CR25","doi-asserted-by":"publisher","first-page":"e1003214","DOI":"10.1371\/journal.ppat.1003214","volume":"9","author":"SB Kutluay","year":"2013","unstructured":"Kutluay SB, Perez-Caballero D, Bieniasz PD. Fates of retroviral core components during unrestricted and TRIM5-restricted infection. PLoS Pathog. 2013;9(3):e1003214. doi:\n10.1371\/journal.ppat.1003214\n\n.","journal-title":"PLoS Pathog"},{"issue":"12","key":"357_CR26","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.4161\/15548627.2014.984278","volume":"10","author":"MA Mandell","year":"2014","unstructured":"Mandell MA, Kimura T, Jain A, Johansen T, Deretic V. TRIM proteins regulate autophagy: TRIM5 is a selective autophagy receptor mediating HIV-1 restriction. Autophagy. 2014;10(12):2387\u20138. doi:\n10.4161\/15548627.2014.984278\n\n.","journal-title":"Autophagy"},{"issue":"7343","key":"357_CR27","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nature09976","volume":"472","author":"T Pertel","year":"2011","unstructured":"Pertel T, Hausmann S, Morger D, Zuger S, Guerra J, Lascano J, et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature. 2011;472(7343):361\u20135. doi:\n10.1038\/nature09976\n\n.","journal-title":"Nature"},{"key":"357_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.virusres.2014.02.013","volume":"184","author":"ME Nepveu-Traversy","year":"2014","unstructured":"Nepveu-Traversy ME, Berthoux L. The conserved sumoylation consensus site in TRIM5alpha modulates its immune activation functions. Virus Res. 2014;184:30\u20138. doi:\n10.1016\/j.virusres.2014.02.013\n\n.","journal-title":"Virus Res"},{"issue":"4","key":"357_CR29","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1128\/JVI.01948-15","volume":"90","author":"EM Campbell","year":"2016","unstructured":"Campbell EM, Weingart J, Sette P, Opp S, Sastri J, O\u2019Connor SK, et al. TRIM5alpha-mediated ubiquitin chain conjugation is required for inhibition of HIV-1 reverse transcription and capsid destabilization. J Virol. 2016;90(4):1849\u201357. doi:\n10.1128\/JVI.01948-15\n\n.","journal-title":"J Virol"},{"issue":"2","key":"357_CR30","doi-asserted-by":"publisher","first-page":"e1000007","DOI":"10.1371\/journal.ppat.1000007","volume":"4","author":"SD Barr","year":"2008","unstructured":"Barr SD, Smiley JR, Bushman FD. The interferon response inhibits HIV particle production by induction of TRIM22. PLoS Pathog. 2008;4(2):e1000007. doi:\n10.1371\/journal.ppat.1000007\n\n.","journal-title":"PLoS Pathog"},{"issue":"1","key":"357_CR31","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1128\/JVI.01810-10","volume":"85","author":"R Singh","year":"2011","unstructured":"Singh R, Gaiha G, Werner L, McKim K, Mlisana K, Luban J, et al. Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection. J Virol. 2011;85(1):208\u201316. doi:\n10.1128\/JVI.01810-10\n\n.","journal-title":"J Virol"},{"issue":"10","key":"357_CR32","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1128\/JVI.02302-10","volume":"85","author":"A Kajaste-Rudnitski","year":"2011","unstructured":"Kajaste-Rudnitski A, Marelli SS, Pultrone C, Pertel T, Uchil PD, Mechti N, et al. TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements. J Virol. 2011;85(10):5183\u201396. doi:\n10.1128\/JVI.02302-10\n\n.","journal-title":"J Virol"},{"key":"357_CR33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12977-015-0230-0","volume":"12","author":"F Turrini","year":"2015","unstructured":"\u2022\u2022 Turrini F, Marelli S, Kajaste-Rudnitski A, Lusic M, Van Lint C, Das AT, et al. HIV-1 transcriptional silencing caused by TRIM22 inhibition of Sp1 binding to the viral promoter. Retrovirology. 2015;12:104. doi:\n10.1186\/s12977-015-0230-0\n\n. A paper showing the mechanism in which TRIM22 inhibits HIV-1 LTR transcriptional activation by inhibition of Sp1","journal-title":"Retrovirology"},{"key":"357_CR34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.virol.2015.09.017","volume":"486","author":"LC Setiawan","year":"2015","unstructured":"Setiawan LC, Kootstra NA. Adaptation of HIV-1 to rhTrim5alpha-mediated restriction in vitro. Virology. 2015;486:239\u201347. doi:\n10.1016\/j.virol.2015.09.017\n\n.","journal-title":"Virology"},{"issue":"14","key":"357_CR35","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1097\/QAD.0000000000000812","volume":"29","author":"EE Nakayama","year":"2015","unstructured":"Nakayama EE, Shioda T. Impact of TRIM5alpha in vivo. AIDS. 2015;29(14):1733\u201343. doi:\n10.1097\/QAD.0000000000000812\n\n.","journal-title":"AIDS"},{"issue":"7353","key":"357_CR36","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/nature10117","volume":"474","author":"N Laguette","year":"2011","unstructured":"Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature. 2011;474(7353):654\u20137. doi:\n10.1038\/nature10117\n\n.","journal-title":"Nature"},{"issue":"7353","key":"357_CR37","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nature10195","volume":"474","author":"K Hrecka","year":"2011","unstructured":"Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature. 2011;474(7353):658\u201361. doi:\n10.1038\/nature10195\n\n.","journal-title":"Nature"},{"key":"357_CR38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1742-4690-9-87","volume":"9","author":"B Descours","year":"2012","unstructured":"Descours B, Cribier A, Chable-Bessia C, Ayinde D, Rice G, Crow Y, et al. SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells. Retrovirology. 2012;9:87. doi:\n10.1186\/1742-4690-9-87\n\n.","journal-title":"Retrovirology"},{"issue":"11","key":"357_CR39","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1038\/nm.2964","volume":"18","author":"HM Baldauf","year":"2012","unstructured":"Baldauf HM, Pan X, Erikson E, Schmidt S, Daddacha W, Burggraf M, et al. SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat Med. 2012;18(11):1682\u20137. doi:\n10.1038\/nm.2964\n\n.","journal-title":"Nat Med"},{"key":"357_CR40","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/1742-4690-9-105","volume":"9","author":"C St Gelais","year":"2012","unstructured":"St Gelais C, de Silva S, Amie SM, Coleman CM, Hoy H, Hollenbaugh JA, et al. SAMHD1 restricts HIV-1 infection in dendritic cells (DCs) by dNTP depletion, but its expression in DCs and primary CD4+ T-lymphocytes cannot be upregulated by interferons. Retrovirology. 2012;9:105. doi:\n10.1186\/1742-4690-9-105\n\n.","journal-title":"Retrovirology"},{"issue":"4","key":"357_CR41","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1515\/hsz-2015-0260","volume":"397","author":"J Ahn","year":"2016","unstructured":"Ahn J. Functional organization of human SAMHD1 and mechanisms of HIV-1 restriction. Biol Chem. 2016;397(4):373\u20139. doi:\n10.1515\/hsz-2015-0260\n\n.","journal-title":"Biol Chem"},{"issue":"7377","key":"357_CR42","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nature10623","volume":"480","author":"DC Goldstone","year":"2011","unstructured":"Goldstone DC, Ennis-Adeniran V, Hedden JJ, Groom HC, Rice GI, Christodoulou E, et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature. 2011;480(7377):379\u201382. doi:\n10.1038\/nature10623\n\n.","journal-title":"Nature"},{"issue":"3","key":"357_CR43","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/ni.2236","volume":"13","author":"H Lahouassa","year":"2012","unstructured":"Lahouassa H, Daddacha W, Hofmann H, Ayinde D, Logue EC, Dragin L, et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol. 2012;13(3):223\u20138. doi:\n10.1038\/ni.2236\n\n.","journal-title":"Nat Immunol"},{"issue":"51","key":"357_CR44","doi-asserted-by":"publisher","first-page":"43596","DOI":"10.1074\/jbc.C111.317628","volume":"286","author":"RD Powell","year":"2011","unstructured":"Powell RD, Holland PJ, Hollis T, Perrino FW. Aicardi-Goutieres syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase. J Biol Chem. 2011;286(51):43596\u2013600. doi:\n10.1074\/jbc.C111.317628\n\n.","journal-title":"J Biol Chem"},{"issue":"44","key":"357_CR45","doi-asserted-by":"publisher","first-page":"26352","DOI":"10.1074\/jbc.M115.677435","volume":"290","author":"C Tang","year":"2015","unstructured":"Tang C, Ji X, Wu L, Xiong Y. Impaired dNTPase activity of SAMHD1 by phosphomimetic mutation of Thr-592. J Biol Chem. 2015;290(44):26352\u20139. doi:\n10.1074\/jbc.M115.677435\n\n.","journal-title":"J Biol Chem"},{"issue":"18","key":"357_CR46","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1038\/emboj.2013.163","volume":"32","author":"J Rehwinkel","year":"2013","unstructured":"Rehwinkel J, Maelfait J, Bridgeman A, Rigby R, Hayward B, Liberatore RA, et al. SAMHD1-dependent retroviral control and escape in mice. EMBO J. 2013;32(18):2454\u201362. doi:\n10.1038\/emboj.2013.163\n\n.","journal-title":"EMBO J"},{"issue":"26","key":"357_CR47","doi-asserted-by":"publisher","first-page":"21570","DOI":"10.1074\/jbc.C112.374843","volume":"287","author":"B Kim","year":"2012","unstructured":"Kim B, Nguyen LA, Daddacha W, Hollenbaugh JA. Tight interplay among SAMHD1 protein level, cellular dNTP levels, and HIV-1 proviral DNA synthesis kinetics in human primary monocyte-derived macrophages. J Biol Chem. 2012;287(26):21570\u20134. doi:\n10.1074\/jbc.C112.374843\n\n.","journal-title":"J Biol Chem"},{"key":"357_CR48","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.virol.2016.05.002","volume":"495","author":"S Bonifati","year":"2016","unstructured":"Bonifati S, Daly MB, St Gelais C, Kim SH, Hollenbaugh JA, Shepard C, et al. SAMHD1 controls cell cycle status, apoptosis and HIV-1 infection in monocytic THP-1 cells. Virology. 2016;495:92\u2013100. doi:\n10.1016\/j.virol.2016.05.002\n\n.","journal-title":"Virology"},{"issue":"12","key":"357_CR49","doi-asserted-by":"publisher","first-page":"8101","DOI":"10.1074\/jbc.M112.431148","volume":"288","author":"N Beloglazova","year":"2013","unstructured":"Beloglazova N, Flick R, Tchigvintsev A, Brown G, Popovic A, Nocek B, et al. Nuclease activity of the human SAMHD1 protein implicated in the Aicardi-Goutieres syndrome and HIV-1 restriction. J Biol Chem. 2013;288(12):8101\u201310. doi:\n10.1074\/jbc.M112.431148\n\n.","journal-title":"J Biol Chem"},{"issue":"8","key":"357_CR50","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/nm.3626","volume":"20","author":"J Ryoo","year":"2014","unstructured":"\u2022\u2022 Ryoo J, Choi J, Oh C, Kim S, Seo M, Kim SY, et al. The ribonuclease activity of SAMHD1 is required for HIV-1 restriction. Nat Med. 2014;20(8):936\u201341. doi:\n10.1038\/nm.3626\n\n. A paper showing that SAMHD1 also needs its RNase activity to inhibit HIV-1 and not just its ability to deplete DNTP levels","journal-title":"Nat Med"},{"issue":"1","key":"357_CR51","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.chom.2014.11.009","volume":"17","author":"GB Kyei","year":"2015","unstructured":"Kyei GB, Cheng X, Ramani R, Ratner L. Cyclin L2 is a critical HIV dependency factor in macrophages that controls SAMHD1 abundance. Cell Host Microbe. 2015;17(1):98\u2013106. doi:\n10.1016\/j.chom.2014.11.009\n\n.","journal-title":"Cell Host Microbe"},{"issue":"12","key":"357_CR52","doi-asserted-by":"publisher","first-page":"e1002425","DOI":"10.1371\/journal.ppat.1002425","volume":"7","author":"A Berger","year":"2011","unstructured":"Berger A, Sommer AF, Zwarg J, Hamdorf M, Welzel K, Esly N, et al. SAMHD1-deficient CD14+ cells from individuals with Aicardi-Goutieres syndrome are highly susceptible to HIV-1 infection. PLoS Pathog. 2011;7(12):e1002425. doi:\n10.1371\/journal.ppat.1002425\n\n.","journal-title":"PLoS Pathog"},{"key":"357_CR53","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.virol.2015.03.012","volume":"479-480","author":"RS Harris","year":"2015","unstructured":"Harris RS, Dudley JP. APOBECs and virus restriction. Virology. 2015;479-480:131\u201345. doi:\n10.1016\/j.virol.2015.03.012\n\n.","journal-title":"Virology"},{"issue":"10","key":"357_CR54","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.4049\/jimmunol.1501504","volume":"195","author":"S Stavrou","year":"2015","unstructured":"Stavrou S, Ross SR. APOBEC3 proteins in viral immunity. J Immunol. 2015;195(10):4565\u201370. doi:\n10.4049\/jimmunol.1501504\n\n.","journal-title":"J Immunol"},{"issue":"18","key":"357_CR55","doi-asserted-by":"publisher","first-page":"9474","DOI":"10.1128\/JVI.01089-09","volume":"83","author":"FA Koning","year":"2009","unstructured":"Koning FA, Newman EN, Kim EY, Kunstman KJ, Wolinsky SM, Malim MH. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol. 2009;83(18):9474\u201385. doi:\n10.1128\/JVI.01089-09\n\n.","journal-title":"J Virol"},{"issue":"3","key":"357_CR56","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1128\/JVI.02587-12","volume":"87","author":"K Gillick","year":"2013","unstructured":"Gillick K, Pollpeter D, Phalora P, Kim EY, Wolinsky SM, Malim MH. Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination. J Virol. 2013;87(3):1508\u201317. doi:\n10.1128\/JVI.02587-12\n\n.","journal-title":"J Virol"},{"issue":"1","key":"357_CR57","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1128\/JVI.00676-12","volume":"87","author":"C Chaipan","year":"2013","unstructured":"Chaipan C, Smith JL, Hu WS, Pathak VK. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. J Virol. 2013;87(1):444\u201353. doi:\n10.1128\/JVI.00676-12\n\n.","journal-title":"J Virol"},{"issue":"6","key":"357_CR58","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0092-8674(03)00423-9","volume":"113","author":"RS Harris","year":"2003","unstructured":"Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, et al. DNA deamination mediates innate immunity to retroviral infection. Cell. 2003;113(6):803\u20139.","journal-title":"Cell"},{"issue":"15","key":"357_CR59","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.cub.2004.06.057","volume":"14","author":"KN Bishop","year":"2004","unstructured":"Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, Malim MH. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Current biology : CB. 2004;14(15):1392\u20136. doi:\n10.1016\/j.cub.2004.06.057\n\n.","journal-title":"Current biology : CB"},{"issue":"6944","key":"357_CR60","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature01709","volume":"424","author":"B Mangeat","year":"2003","unstructured":"Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 2003;424(6944):99\u2013103. doi:\n10.1038\/nature01709\n\n.","journal-title":"Nature"},{"key":"357_CR61","doi-asserted-by":"publisher","unstructured":"Okada A, Iwatani Y. APOBEC3G-mediated G-to-A hypermutation of the HIV-1 genome: the missing link in antiviral molecular mechanisms. Front Microbiol. 2016;7:2027. doi:\n10.3389\/fmicb.2016.02027\n\n.\u200b\u00a0","DOI":"10.3389\/fmicb.2016.02027"},{"key":"357_CR62","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1742-4690-6-16","volume":"6","author":"RA Russell","year":"2009","unstructured":"Russell RA, Moore MD, Hu WS, Pathak VK. APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA. Retrovirology. 2009;6:16. doi:\n10.1186\/1742-4690-6-16\n\n.","journal-title":"Retrovirology"},{"issue":"1","key":"357_CR63","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.virol.2008.04.012","volume":"377","author":"T Wang","year":"2008","unstructured":"Wang T, Zhang W, Tian C, Liu B, Yu Y, Ding L, et al. Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C. Virology. 2008;377(1):71\u20139. doi:\n10.1016\/j.virol.2008.04.012\n\n.","journal-title":"Virology"},{"key":"357_CR64","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1742-4690-6-56","volume":"6","author":"YN Friew","year":"2009","unstructured":"Friew YN, Boyko V, Hu WS, Pathak VK. Intracellular interactions between APOBEC3G, RNA, and HIV-1 Gag: APOBEC3G multimerization is dependent on its association with RNA. Retrovirology. 2009;6:56. doi:\n10.1186\/1742-4690-6-56\n\n.","journal-title":"Retrovirology"},{"issue":"6","key":"357_CR65","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.jmb.2013.10.033","volume":"426","author":"BA Desimmie","year":"2014","unstructured":"Desimmie BA, Delviks-Frankenberrry KA, Burdick RC, Qi D, Izumi T, Pathak VK. Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J Mol Biol. 2014;426(6):1220\u201345. doi:\n10.1016\/j.jmb.2013.10.033\n\n.","journal-title":"J Mol Biol"},{"key":"357_CR66","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3389\/fmicb.2014.00450","volume":"5","author":"Y Feng","year":"2014","unstructured":"Feng Y, Baig TT, Love RP, Chelico L. Suppression of APOBEC3-mediated restriction of HIV-1 by Vif. Front Microbiol. 2014;5:450. doi:\n10.3389\/fmicb.2014.00450\n\n.","journal-title":"Front Microbiol"},{"issue":"11","key":"357_CR67","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1038\/nm945","volume":"9","author":"AM Sheehy","year":"2003","unstructured":"Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med. 2003;9(11):1404\u20137. doi:\n10.1038\/nm945\n\n.","journal-title":"Nat Med"},{"issue":"4","key":"357_CR68","doi-asserted-by":"publisher","first-page":"e1000367","DOI":"10.1371\/journal.ppat.1000367","volume":"5","author":"P Jern","year":"2009","unstructured":"Jern P, Russell RA, Pathak VK, Coffin JM. Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS Pathog. 2009;5(4):e1000367. doi:\n10.1371\/journal.ppat.1000367\n\n.","journal-title":"PLoS Pathog"},{"issue":"7","key":"357_CR69","doi-asserted-by":"publisher","first-page":"e1004281","DOI":"10.1371\/journal.ppat.1004281","volume":"10","author":"EY Kim","year":"2014","unstructured":"Kim EY, Lorenzo-Redondo R, Little SJ, Chung YS, Phalora PK, Maljkovic Berry I, et al. Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection. PLoS Pathog. 2014;10(7):e1004281. doi:\n10.1371\/journal.ppat.1004281\n\n.","journal-title":"PLoS Pathog"},{"issue":"7472","key":"357_CR70","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature12542","volume":"502","author":"C Goujon","year":"2013","unstructured":"\u2022\u2022 Goujon C, Moncorge O, Bauby H, Doyle T, Ward CC, Schaller T, et al. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature. 2013;502(7472):559\u201362. doi:\n10.1038\/nature12542\n\n. One of the three major papers released in 2013 first describing MX2 as an ISG that is also a restriction factor","journal-title":"Nature"},{"issue":"7472","key":"357_CR71","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature12653","volume":"502","author":"M Kane","year":"2013","unstructured":"\u2022\u2022 Kane M, Yadav SS, Bitzegeio J, Kutluay SB, Zang T, Wilson SJ, et al. MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature. 2013;502(7472):563\u20136. doi:\n10.1038\/nature12653\n\n. One of the three major papers released in 2013 first describing MX2 as an ISG that is also a restriction factor","journal-title":"Nature"},{"issue":"4","key":"357_CR72","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.chom.2013.08.015","volume":"14","author":"Z Liu","year":"2013","unstructured":"\u2022\u2022 Liu Z, Pan Q, Ding S, Qian J, Xu F, Zhou J, et al. The interferon-inducible MxB protein inhibits HIV-1 infection. Cell Host Microbe. 2013;14(4):398\u2013410. doi:\n10.1016\/j.chom.2013.08.015\n\n. One of the three major papers released in 2013 first describing MX2 as an ISG that is also a restriction factor","journal-title":"Cell Host Microbe"},{"key":"357_CR73","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12977-014-0068-x 10.1186\/PREACCEPT-6453674081373986","volume":"11","author":"T Fricke","year":"2014","unstructured":"Fricke T, White TE, Schulte B, de Souza Aranha Vieira DA, Dharan A, Campbell EM, et al. MxB binds to the HIV-1 core and prevents the uncoating process of HIV-1. Retrovirology. 2014;11:68. doi:\n10.1186\/s12977-014-0068-x 10.1186\/PREACCEPT-6453674081373986\n\n.","journal-title":"Retrovirology"},{"key":"357_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12977-014-0129-1","volume":"12","author":"Z Liu","year":"2015","unstructured":"Liu Z, Pan Q, Liang Z, Qiao W, Cen S, Liang C. The highly polymorphic cyclophilin A-binding loop in HIV-1 capsid modulates viral resistance to MxB. Retrovirology. 2015;12:1. doi:\n10.1186\/s12977-014-0129-1\n\n.","journal-title":"Retrovirology"},{"key":"357_CR75","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12977-014-0090-z","volume":"11","author":"KA Matreyek","year":"2014","unstructured":"Matreyek KA, Wang W, Serrao E, Singh PK, Levin HL, Engelman A. Host and viral determinants for MxB restriction of HIV-1 infection. Retrovirology. 2014;11:90. doi:\n10.1186\/s12977-014-0090-z\n\n.","journal-title":"Retrovirology"},{"issue":"4","key":"357_CR76","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1089\/jir.2012.0133","volume":"33","author":"E Mavrommatis","year":"2013","unstructured":"Mavrommatis E, Fish EN, Platanias LC. The schlafen family of proteins and their regulation by interferons. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research. 2013;33(4):206\u201310. doi:\n10.1089\/jir.2012.0133\n\n.","journal-title":"Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research"},{"issue":"7422","key":"357_CR77","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nature11433","volume":"491","author":"M Li","year":"2012","unstructured":"Li M, Kao E, Gao X, Sandig H, Limmer K, Pavon-Eternod M, et al. Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11. Nature. 2012;491(7422):125\u20138. doi:\n10.1038\/nature11433\n\n.","journal-title":"Nature"},{"key":"357_CR78","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/1742-4690-10-106","volume":"10","author":"M Abdel-Mohsen","year":"2013","unstructured":"Abdel-Mohsen M, Raposo RA, Deng X, Li M, Liegler T, Sinclair E, et al. Expression profile of host restriction factors in HIV-1 elite controllers. Retrovirology. 2013;10:106. doi:\n10.1186\/1742-4690-10-106\n\n.","journal-title":"Retrovirology"},{"issue":"12","key":"357_CR79","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/nm.3956","volume":"21","author":"T Tada","year":"2015","unstructured":"\u2022\u2022 Tada T, Zhang Y, Koyama T, Tobiume M, Tsunetsugu-Yokota Y, Yamaoka S, et al. MARCH8 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins. Nat Med. 2015;21(12):1502\u20137. doi:\n10.1038\/nm.3956\n\n. A study demonstrating how MARCH8 inhibits HIV-1 replication in macrophages by limiting envelopes incorporation into budding virions","journal-title":"Nat Med"},{"issue":"7177","key":"357_CR80","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nature06553","volume":"451","author":"SJ Neil","year":"2008","unstructured":"Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature. 2008;451(7177):425\u201330. doi:\n10.1038\/nature06553\n\n.","journal-title":"Nature"},{"issue":"10","key":"357_CR81","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1034\/j.1600-0854.2003.00129.x","volume":"4","author":"S Kupzig","year":"2003","unstructured":"Kupzig S, Korolchuk V, Rollason R, Sugden A, Wilde A, Banting G. Bst-2\/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic. 2003;4(10):694\u2013709.","journal-title":"Traffic"},{"issue":"3","key":"357_CR82","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.cell.2009.08.039","volume":"139","author":"D Perez-Caballero","year":"2009","unstructured":"Perez-Caballero D, Zang T, Ebrahimi A, McNatt MW, Gregory DA, Johnson MC, et al. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell. 2009;139(3):499\u2013511. doi:\n10.1016\/j.cell.2009.08.039\n\n.","journal-title":"Cell"},{"issue":"5","key":"357_CR83","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.chom.2012.10.007","volume":"12","author":"RP Galao","year":"2012","unstructured":"Galao RP, Le Tortorec A, Pickering S, Kueck T, Neil SJ. Innate sensing of HIV-1 assembly by tetherin induces NFkappaB-dependent proinflammatory responses. Cell Host Microbe. 2012;12(5):633\u201344. doi:\n10.1016\/j.chom.2012.10.007\n\n.","journal-title":"Cell Host Microbe"},{"issue":"4","key":"357_CR84","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1128\/JVI.02272-12","volume":"87","author":"A Tokarev","year":"2013","unstructured":"Tokarev A, Suarez M, Kwan W, Fitzpatrick K, Singh R, Guatelli J. Stimulation of NF-kappaB activity by the HIV restriction factor BST2. J Virol. 2013;87(4):2046\u201357. doi:\n10.1128\/JVI.02272-12\n\n.","journal-title":"J Virol"},{"issue":"5","key":"357_CR85","doi-asserted-by":"publisher","first-page":"e1000429","DOI":"10.1371\/journal.ppat.1000429","volume":"5","author":"B Jia","year":"2009","unstructured":"Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, Fofana IB, et al. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin\/BST2. PLoS Pathog. 2009;5(5):e1000429. doi:\n10.1371\/journal.ppat.1000429\n\n.","journal-title":"PLoS Pathog"},{"issue":"5","key":"357_CR86","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.chom.2014.10.002","volume":"16","author":"SF Kluge","year":"2014","unstructured":"Kluge SF, Mack K, Iyer SS, Pujol FM, Heigele A, Learn GH, et al. Nef proteins of epidemic HIV-1 group O strains antagonize human tetherin. Cell Host Microbe. 2014;16(5):639\u201350. doi:\n10.1016\/j.chom.2014.10.002\n\n.","journal-title":"Cell Host Microbe"},{"issue":"4","key":"357_CR87","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2174\/157016212800792496","volume":"10","author":"R Serra-Moreno","year":"2012","unstructured":"Serra-Moreno R, Evans DT. Adaptation of human and simian immunodeficiency viruses for resistance to tetherin\/BST-2. Curr HIV Res. 2012;10(4):277\u201382.","journal-title":"Curr HIV Res"},{"issue":"9","key":"357_CR88","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1128\/JVI.01800-08","volume":"83","author":"M Dube","year":"2009","unstructured":"Dube M, Roy BB, Guiot-Guillain P, Mercier J, Binette J, Leung G, et al. Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. J Virol. 2009;83(9):4574\u201390. doi:\n10.1128\/JVI.01800-08\n\n.","journal-title":"J Virol"},{"issue":"4","key":"357_CR89","doi-asserted-by":"publisher","first-page":"e1003299","DOI":"10.1371\/journal.ppat.1003299","volume":"9","author":"MW McNatt","year":"2013","unstructured":"McNatt MW, Zang T, Bieniasz PD. Vpu binds directly to tetherin and displaces it from nascent virions. PLoS Pathog. 2013;9(4):e1003299. doi:\n10.1371\/journal.ppat.1003299\n\n.","journal-title":"PLoS Pathog"},{"issue":"7572","key":"357_CR90","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/nature15400","volume":"526","author":"Y Usami","year":"2015","unstructured":"\u2022\u2022 Usami Y, Wu Y, Gottlinger HG. SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef. Nature. 2015;526(7572):218\u201323. doi:\n10.1038\/nature15400\n\n. One of the first papers published on SERINC3\/5 and how it restricts HIV-1 and is antagonized by Nef","journal-title":"Nature"},{"issue":"42","key":"357_CR91","doi-asserted-by":"publisher","first-page":"35776","DOI":"10.1074\/jbc.M505712200","volume":"280","author":"M Inuzuka","year":"2005","unstructured":"Inuzuka M, Hayakawa M, Ingi T. Serinc, an activity-regulated protein family, incorporates serine into membrane lipid synthesis. J Biol Chem. 2005;280(42):35776\u201383. doi:\n10.1074\/jbc.M505712200\n\n.","journal-title":"J Biol Chem"},{"issue":"11","key":"357_CR92","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1086\/652420","volume":"201","author":"DM Asmuth","year":"2010","unstructured":"Asmuth DM, Murphy RL, Rosenkranz SL, Lertora JJ, Kottilil S, Cramer Y, et al. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. The Journal of infectious diseases. 2010;201(11):1686\u201396. doi:\n10.1086\/652420\n\n.","journal-title":"The Journal of infectious diseases"},{"issue":"2","key":"357_CR93","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1124\/mi.9.2.5","volume":"9","author":"CS Adamson","year":"2009","unstructured":"Adamson CS, Freed EO. Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets. Mol Interv. 2009;9(2):70\u20134. doi:\n10.1124\/mi.9.2.5\n\n.","journal-title":"Mol Interv"},{"issue":"4","key":"357_CR94","doi-asserted-by":"publisher","first-page":"e451","DOI":"10.1016\/j.ddtec.2013.07.002","volume":"10","author":"TE Smithgall","year":"2013","unstructured":"Smithgall TE, Thomas G. Small molecule inhibitors of the HIV-1 virulence factor, Nef. Drug Discovery Today. Technologies. 2013;10(4):e451\u2013548. doi:\n10.1016\/j.ddtec.2013.07.002\n\n.","journal-title":"Drug Discovery Today. Technologies"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-017-0357-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11904-017-0357-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-017-0357-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,10]],"date-time":"2017-05-10T05:30:01Z","timestamp":1494394201000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11904-017-0357-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,2]]},"references-count":94,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["357"],"URL":"https:\/\/doi.org\/10.1007\/s11904-017-0357-9","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,2]]}}}